Position
Renaissance Technologies in Prelude Therapeutics Inc
Back to the book · All holders of PRLD
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $525.6K$3.42 → $5.33
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 271.3K | $786.8K | — | — | — | 0.0% |
| Q1 2026 | 275.2K | $941.2K | $3.42 | $141.1K | $13.3K | 0.0% |
| Q2 2026 | 281.2K | $1.5M | $5.33 | $525.6K | $32K | 0.0% |